TRDA — Entrada Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$7.07
+$0.02 (+0.28%)
Entrada Therapeutics Inc (TRDA) is a biotechnology company listed on NASDAQ. It is led by Dipal Doshi, based in One Design Center Place, Boston, MA, United States, 02210, with about 183 employees. Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest reported TRDA revenue for 2025-09-30 was $1.6M. Net income was -$104.6M. Revenue was down 17.2% from 2025-06-30 to 2025-09-30. TRDA currently screens at market cap $274.4M and trailing P/E 12.5.
Use this TRDA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TRDA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TRDA SEC filings page. Lician reads the product cache first so this HTML stays unique to Entrada Therapeutics Inc even when a live quote feed is slow.
About Entrada Therapeutics Inc
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. The company's EEV platform develops products based on oligonucleotide, enzyme, and antibody-conjugated EEV peptides. Its therapeutic candidates, which include ENTR-601-44 that is in Phase 1 clinical trial for the treatment of Duchenne muscular dystrophy; and VX-670, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45, ENTR-601-50, and ENTR-601-51, which are in preclinical trial, for the treatment of Duchenne muscular dystrophy; and PTI-501, an intracellular thymidine phosphorylase enzyme replacement therapy for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. It has strategic collaboration and license agreements with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize VX-670; and Pierrepont Therapeutics, Inc. to advance the development of PTI-501. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
TRDA Key Statistics
Market Cap
$274.40M
Volume
32,898
Previous Close
$7.33
Day Range
$7.39 – $7.67
P/E Ratio
12.47
EPS
$1.68
Revenue
$210.78M
Net Income
$65.63M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+63.4%
Profit Margin
31.1%
Employees
183
TRDA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $210.78M | $129.01M | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $65.63M | -$6.68M | -$94.62M | -$51.16M |
| EPS (Diluted) | $1.68 | -$0.20 | -$3.02 | -$8.16 |
Total Assets
$526.32M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$500.00K
Operating Cash Flow
-$41.56M
Free Cash Flow
$0.00
Entrada Therapeutics Inc Company Information
- CEO & Director
- Dipal Doshi
- Headquarters
- One Design Center Place, Boston, MA, United States, 02210
- Website
- www.entradatx.com
- Phone
- 857 520 9158
- IPO / Founded
- 2021-10-29
- Sector
- Healthcare
- Industry
- Biotechnology